Best pharma stocks in 2026 — ranked by real data
Every listed company in the Medicine, pharma & life science value chain (53 stocks), mechanically ranked by actual market data — no opinions, no January listicle. Re-ranked every trading day.
As of July 12, 2026, the strongest pharma stock this year is Moderna (MRNA, +131.5% YTD), while Eli Lilly leads on size at $1.1T. Unlike a listicle written in January, this page re-ranks itself every trading day from real market data.
Top 10 by return this year
Total return YTD, prices adjusted for splits and dividends.
| # | Company | YTD return | 1Y return | Market cap |
|---|---|---|---|---|
| 1 | ModernaMRNABiotech & innovation | +131.5% | +99.2% | $27.1B |
| 2 | IlluminaILMNLife science tools | +45.0% | +90.1% | $28.8B |
| 3 | CVS HealthCVSDistribution & pharmacy infrastructure | +31.2% | +58.7% | $133B |
| 4 | UnitedHealthUNHDistribution & pharmacy infrastructure | +28.6% | +41.8% | $386B |
| 5 | West Pharmaceutical ServicesWSTCDMO & pharma manufacturing | +28.6% | +54.3% | $24.7B |
| 6 | Neurocrine BiosciencesNBIXBiotech & innovation | +24.9% | +31.3% | $17.8B |
| 7 | Johnson & JohnsonJNJBig pharma | +24.2% | +63.0% | $619B |
| 8 | Quest DiagnosticsDGXDiagnostics | +19.5% | +21.0% | $23B |
| 9 | Baxter InternationalBAXMedtech & devices | +18.4% | −23.8% | $11.7B |
| 10 | IncyteINCYBiotech & innovation | +18.2% | +65.9% | $23.3B |
Data as of 2026-07-12 · updates daily after U.S. close
The 10 largest by market cap
The heavyweights of the pharma chain.
| # | Company | Market cap | Today | P/E |
|---|---|---|---|---|
| 1 | Eli LillyLLYDiabetes & metabolic disease | $1.1T | −2.3% | 44.3 |
| 2 | Johnson & JohnsonJNJBig pharma | $619B | −0.8% | 29.4 |
| 3 | AbbVieABBVBig pharma | $438B | −0.7% | 120.6 |
| 4 | UnitedHealthUNHDistribution & pharmacy infrastructure | $386B | −1.6% | 32.0 |
| 5 | Merck & Co.MRKBig pharma | $305B | −1.2% | 34.1 |
| 6 | AmgenAMGNBiotech & innovation | $196B | −0.1% | 25.1 |
| 7 | Thermo Fisher ScientificTMOLife science tools | $196B | +0.4% | 28.6 |
| 8 | Abbott LaboratoriesABTDiagnostics | $164B | −0.5% | 26.1 |
| 9 | Gilead SciencesGILDBiotech & innovation | $161B | −3.7% | 17.5 |
| 10 | Intuitive SurgicalISRGMedtech & devices | $144B | −1.2% | 48.4 |
Lowest valuation (P/E)
Lowest positive trailing P/E — cheap can be cheap for a reason; see each profile for the risks.
| # | Company | P/E | P/S | Market cap |
|---|---|---|---|---|
| 1 | The Cigna GroupCIDistribution & pharmacy infrastructure | 12.3 | 0.3 | $77.6B |
| 2 | ZoetisZTSBig pharma | 12.4 | 3.5 | $32.9B |
| 3 | GE HealthCareGEHCMedtech & devices | 15.4 | 1.4 | $29.4B |
| 4 | RegeneronREGNBiotech & innovation | 15.7 | 4.7 | $69.7B |
| 5 | IncyteINCYBiotech & innovation | 16.3 | 4.3 | $23.3B |
| 6 | Gilead SciencesGILDBiotech & innovation | 17.5 | 5.4 | $161B |
| 7 | United TherapeuticsUTHRBiotech & innovation | 18.0 | 7.3 | $23.2B |
| 8 | PfizerPFEBig pharma | 18.4 | 2.2 | $138B |
| 9 | Boston ScientificBSXMedtech & devices | 18.7 | 3.2 | $66.5B |
| 10 | ResMedRMDMedtech & devices | 19.5 | 5.3 | $29.6B |
Methodology: the universe is Sectivia's curated Medicine, pharma & life science value chain — U.S.-listed companies grouped by their role in the chain. Rankings are purely mechanical from daily Finnhub data. "Best" here means best on the stated metric, not a recommendation. Companies without data for a metric are excluded from that table.
See all 53 companies on the interactive Pharma value-chain map — segments, supply-chain links and daily metrics.Open the Pharma map →